Lino L. Teichmann

Bonn, NW 53127, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications

DECIDER-2: Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy.

DECIDER-2: Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy.

Journal: BMC cancer
Published: June 16, 2026

Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX).

Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX).

Journal: Leukemia
Published: October 28, 2025

Frequent and clinically relevant germline DNA repair gene variants in young and familial myeloproliferative neoplasms.

Frequent and clinically relevant germline DNA repair gene variants in young and familial myeloproliferative neoplasms.

Journal: Blood cancer journal
Published: September 18, 2025

A phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

A phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

Journal: Blood
Published: July 09, 2025

Phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

Phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

Journal: Blood
Published: July 09, 2025

Tissue inflammation induced by constitutively active STING is mediated by enhanced TNF signaling.

Tissue inflammation induced by constitutively active STING is mediated by enhanced TNF signaling.

Journal: eLife
Published: July 08, 2024

Mitigation of atrial fibrillation-related complications with antithrombotic and cytoreductive therapy in patients with Myeloproliferative Neoplasms: Implications from the GSG-MPN bioregistry.

Mitigation of atrial fibrillation-related complications with antithrombotic and cytoreductive therapy in patients with Myeloproliferative Neoplasms: Implications from the GSG-MPN bioregistry.

Journal: HemaSphere
Published: June 01, 2024

MoReLife - real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients.

MoReLife - real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients.

Journal: Annals of hematology
Published: May 20, 2024

Refinement of the prognostic impact of somatic CEBPA bZIP domain mutations in acute myeloid leukemia: Results of the AML Study Group (AMLSG).

Refinement of the prognostic impact of somatic CEBPA bZIP domain mutations in acute myeloid leukemia: Results of the AML Study Group (AMLSG).

Journal: HemaSphere
Published: April 12, 2024

NLRP3-induced systemic inflammation controls the development of JAK2V617F mutant myeloproliferative neoplasms.

NLRP3-induced systemic inflammation controls the development of JAK2V617F mutant myeloproliferative neoplasms.

Journal: Nature communications
Published: March 14, 2024

Platelet transcription factors license the pro-inflammatory cytokine response of human monocytes.

Platelet transcription factors license the pro-inflammatory cytokine response of human monocytes.

Journal: EMBO molecular medicine
Published: November 14, 2023

Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study.

Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study.

Journal: Annals of hematology
Published: March 30, 2023
Showing 1-12 of 26

Last Updated: 09/26/2026